PDS Biotechnology saw a surge in its shares by 20% to $6.30 following the release of its third-quarter financial results. The clinical-stage immunotherapy company reported a quarterly loss of $10.8 million, or 35 cents a share. This is a narrower loss compared to the $7.4 million, or 26 cents a share, loss in the same quarter last year.

Analysts polled by FactSet were anticipating a higher loss of $14.4 million, or 38 cents a share. The company attributed its higher quarterly loss to an increase in research and development expenses, along with general and administrative expenses.

Research and development expenses rose to $6.4 million in the third quarter from $4.4 million in the previous year. The increase of $2 million can be primarily attributed to a rise in clinical trials expenses by $1.3 million, and an increase in personnel costs including $700,000 in non-cash stock-based compensation.

Despite the loss, PDS Biotech reported a healthy cash balance of $54.3 million as of September 30. The company is confident that its available cash resources will sustain its operational and research and development activities until the third quarter of 2024.

Write Your Comment